| Autor: |
d'Apolito M; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Ranaldi A; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Santoro F; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.; Cardiology Unit, University Polyclinic Hospital of Foggia, 71122 Foggia, Italy., Cannito S; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Gravina M; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Santacroce R; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Ragnatela I; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy., Margaglione A; Cardiology Unit, University Polyclinic Hospital of Foggia, 71122 Foggia, Italy., D'Andrea G; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy., Casavecchia G; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.; Cardiology Unit, University Polyclinic Hospital of Foggia, 71122 Foggia, Italy., Brunetti ND; Department of Medical and Surgical Sciences, University of Foggia, 71122 Foggia, Italy.; Cardiology Unit, University Polyclinic Hospital of Foggia, 71122 Foggia, Italy., Margaglione M; Medical Genetics, Department of Clinical and Experimental Medicine, University of Foggia, 71122 Foggia, Italy. |
| Abstrakt: |
Dystrophin ( DMD ) gene mutations are associated with skeletal muscle diseases such as Duchenne and Becker Muscular Dystrophy (BMD) and X-linked dilated cardiomyopathy (XL-DCM). To investigate the molecular basis of DCM in a 37-year-old woman. Clinical and genetic investigations were performed. Genetic testing was performed with whole exome sequencing (WES) using the Illumina platform. According to the standard protocol, a variant found by WES was confirmed in all available members of the family by bi-directional capillary Sanger resequencing. The effect of the variant was investigated by using an in silico prediction of pathogenicity. The index case was a 37-year-old woman diagnosed with DCM at the age of 33. A germline heterozygous A>G transversion at nucleotide 10103 in the DMD gene, leading to an aspartic acid-glycine substitution at the amino acid 3368 of the DMD protein (c.10103A>G p.Asp3368Gly), was identified and confirmed by PCR-based Sanger sequencing of the exon 70. In silico prediction suggests that this variant could have a deleterious impact on protein structure and functionality (CADD = 30). The genetic analysis was extended to the first-degree relatives of the proband (mother, father, and sister) and because of the absence of the variant in both parents, the p.Asp3368Gly substitution was considered as occurring de novo. Then, the direct sequencing analysis of her 8-year-old son identified as hemizygous for the same variant. The young patient did not present any signs or symptoms attributable to DCM, but reported asthenia and presented with bilateral calf hypertrophy at clinical examination. Laboratory testing revealed increased levels of creatinine kinase (maximum value of 19,000 IU/L). We report an early presentation of dilated cardiomyopathy in a 33-year-old woman due to a de novo pathogenic variant of the dystrophin ( DMD ) gene (p.Asp3368Gly). Genetic identification of this variant allowed an early diagnosis of a skeletal muscle disease in her son. |
